The Wegovy pill's introductory price ended today. As of April 15, 2026, the 4mg oral semaglutide dose costs $199 per month for self-pay patients — up from the $149 launch price Novo Nordisk introduced in January. [1]

This paper noted yesterday that the deadline was arriving. It has arrived.

The price structure from here: $199 for the first two months at the 4mg dose, then $299 once patients titrate to the 9mg or 25mg maintenance doses. The 1.5mg starting dose remains at $149. For patients who began in January at the introductory rate and have been titrating up on schedule, the cost of staying on the drug has roughly doubled in three months. [1]

The $149 price was never permanent. Novo Nordisk's launch materials described it as an introductory offer, and the April 15 expiration was disclosed in fine print across pharmacy chains, GoodRx, and the company's own patient portal. But introductory prices are marketing instruments — they set an anchor, attract patients, and establish a habit before the real pricing structure kicks in. By that metric, Novo Nordisk's launch was successful. [2]

The comparison that matters is not $149 versus $199. It is oral versus injectable. The Wegovy injection — the pen-form semaglutide that preceded the pill by several years — carries a cash price of roughly $1,300 per month without insurance. At $199, the oral pill is still dramatically cheaper for self-pay patients. [2]

But "cheaper than the injection" is not the same as "affordable." Obesity affects approximately 40% of American adults, the majority of whom are not wealthy. The patients most likely to need long-term GLP-1 therapy are also the patients least likely to sustain $199 monthly out-of-pocket costs. Insurance coverage for GLP-1 medications remains patchy — most commercial plans cover Wegovy for qualifying obesity diagnoses, but coverage determinations, prior authorization requirements, and step therapy protocols create barriers that fall disproportionately on lower-income patients. [1]

Novo Nordisk launched the pill at $149 to compete with compounders — telehealth companies that had been producing cheaper semaglutide through 503B outsourcing facilities during the years-long Wegovy injection shortage. The FDA's removal of semaglutide from the shortage list in 2025 effectively ended the compounding window, concentrating the market back to Novo Nordisk.

The price increase today is the logical next step in that sequence: attract patients from compounders, establish the drug as the default, then price for profitability. It is a business model, not a betrayal. But it is a business model applied to a medication that functions, for many patients, more like insulin than like a lifestyle supplement — something they must take continuously to maintain its effects.

The clinical evidence on what happens when patients stop semaglutide is consistent: weight returns, often rapidly. That continuity requirement is what makes the April 15 price increase more than a billing adjustment.

-- NORA WHITFIELD, Chicago